Navigating Access to Generic Therapy

2020-12-21T15:27:15-05:00September 14th, 2018|

The Pulmonary Hypertension Association (PHA) reported Aug. 17 that generic tadalafil was approved by the Food and Drug Administration (FDA) and suggested that pulmonary hypertension (PH) patients taking Adcirca® discuss the implications with their care teams. Since then, generic tadalafil has become available through many health insurance plans. In addition, PHA has been advised

Share Your Oxygen Experiences: PHA Responds to Proposed Changes to Medicare Oxygen Coverage

2020-12-21T15:27:17-05:00September 7th, 2018|

The Centers for Medicare and Medicaid Services (CMS) has proposed significant changes to how home oxygen (also known as supplemental oxygen) is regulated and paid for. The Pulmonary Hypertension Association (PHA) is taking action to improve the pulmonary hypertension (PH) community’s experience accessing home oxygen. If you have been prescribed home oxygen, you can help

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2020-12-21T15:25:56-05:00August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

Caution: Accumulator Adjustment Programs at Work

2020-12-21T15:25:58-05:00August 30th, 2018|

Accumulator adjustment programs are a cost-management strategy some pharmacy benefit managers (PBMs) are using that may place a significant financial burden on individuals with pulmonary hypertension (PH) and other complex, costly health conditions. When an insurance plan uses an accumulator adjustment program, copay discount cards and other forms of manufacturer assistance do not apply

FDA Approves Generic Version of Adcirca®; Additional Approvals May Come Soon

2020-12-21T15:26:03-05:00August 17th, 2018|

The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.

Learning to Live Your Best Life: Join PHA on the Road in 2018

2020-12-21T15:26:10-05:00August 3rd, 2018|

The Pulmonary Hypertension Association (PHA) announces the dates and cities for two PHA on the Road: PH Patients and Families Education Forums for 2018. Forums are scheduled in Long Beach, Calif., September 29, and Milwaukee, October 27. PHA on the Road, a program of the PHA Medical Education Fund,* provides a unique opportunity for

PHA Brings Your Voice to Capitol Hill: Treatment Access and Quality Care

2020-12-21T15:25:10-05:00July 27th, 2018|

During the past month, the Pulmonary Hypertension Association (PHA) and members of the pulmonary hypertension (PH) community have communicated with Congress in unique ways. Hundreds of attendees at PHA’s 2018 International PH Conference and Scientific Sessions signed a petition asking Congress to fund a PH program at the Centers for Disease Control and Prevention

NEW! PHA Roadmap to Hope a must-read resource for people newly diagnosed with PH

2020-12-21T15:24:02-05:00June 20th, 2018|

The Pulmonary Hypertension Association (PHA) has created a new resource for people who have recently been – or are at risk of being – diagnosed with pulmonary hypertension (PH). The Roadmap to Hope: a guide for people recently diagnosed with pulmonary hypertension (PH) answers the question, “I have PH – now what do I

PHA Educates Congress about PH During Capitol Hill Lunch

2020-12-21T15:24:07-05:00June 8th, 2018|

The Pulmonary Hypertension Association (PHA) hosted a lunch briefing in Washington, DC, Wednesday, June 6, for members of Congress and their staff. Oksana A. Shlobin, MD, FCCP, a director of the Pulmonary Hypertension Program at Inova Fairfax Hospital, educated attendees about pulmonary hypertension (PH), what it is and how it is treated. PH community